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httpcense.Abstract Background: Metabolic syndrome is a group of metabolic conditions that occur
together representing a combination of cardiovascular risk determinants such as obesity, insulin
resistance and lipid abnormalities such as hypertriglyceridemia, increased free fatty acids, low
high-density-cholesterol and hypertension. Interleukin-6 (IL-6), is a 20.5 kDa protein that induces
the expression of acute phase proteins and it is secreted by many different cell types.
Aim of this work: To study the incidence of metabolic syndrome in COPD patients and to eval-
uate the role of IL 6 as a potent inﬂammatory marker in COPD patients with or without metabolic
syndrome.
Patients and methods: IL 6 levels were assayed in 50 patients diagnosed as having COPD with or
without metabolic syndrome (patient group) as well as in 35 age and sex matched apparently
healthy non smoker volunteers with no history of chronic chest troubles (control group) using
the enzyme linked immunosorbent assay (ELISA) technique.
Results: It was found that there were statistically signiﬁcant differences between the two groups
regarding the incidence of metabolic syndrome (P value = 0.0438). There was highly statistically
signiﬁcant difference between the two groups regarding the serum IL 6 level (P value <0.0001).
Conclusion: In conclusion, our ﬁndings suggest that the features of the metabolic syndrome may
be frequent in patients with COPD than in the general population, so it is recommended to screen
all the COPD patients for associated metabolic syndrome as well as elevated levels of inﬂammatory
mediators including IL 6.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.01001649587.
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Chronic obstructive pulmonary disease is a leading cause of
morbidity and mortality worldwide [1,2], and its prevalence
is rising [3]. It occurs predominantly in tobacco smokers and
is characterized by an increase in the annual rate of decline
of forced expiratory volume in 1 s (FEV1) [4]. As lung functionis. Production and hosting by Elsevier B.V. All rights reserved.
2.007
Table 1 Pulmonary function tests of the COPD group.
(%) Patients
FEV1 54.3 ± 15.9
FEV1/FVC 62.2 ± 4.1
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
86 H. Hosny et al.deteriorates, substantial changes in general health occur [5].
Smoking cessation reduces the rate of decline in FEV1 in peo-
ple with this disease [6] but no pharmacological intervention
has been shown to modify the progression of disease or the
associated decline in health status.
In patients with chronic diseases such as chronic obstructive
pulmonary disease (COPD), unrelated disorders are relatively
underrecognized [7]. However, the mechanisms responsible
for this association remain largely unknown [8,9].
Metabolic syndrome, also called insulin resistance syn-
drome or syndrome X, is a cluster of risk factors that is respon-
sible for much of the excess cardiovascular disease morbidity
among overweight and obese patients and those persons with
type 2 diabetes mellitus [10].
A report from the National Cholesterol Education Pro-
gram–Adult Treatment Panel (NCEP–ATP III) identiﬁed met-
abolic syndrome as an independent risk factor for
cardiovascular disease and considered it an indication for
intensive lifestyle modiﬁcation [11].
The major characteristics of metabolic syndrome include
insulin resistance, abdominal obesity, elevated blood pressure,
and lipid abnormalities (i.e., elevated levels of triglycerides and
low levels of high-density lipoprotein [HDL] cholesterol).
The etiology of the metabolic syndrome has not been estab-
lished deﬁnitively. One hypothesis presumes that the primary
cause is insulin resistance [12].
The second hypothesis blames hormonal changes for the
development of abdominal obesity. One study demonstrated
that persons with elevated levels of serum cortisol (caused by
chronic stress) developed abdominal obesity, insulin resistance,
and lipid abnormalities [13].
The ATP III guidelines deﬁne the metabolic syndrome as a
new secondary target for cardiovascular risk reduction therapy
beyond lowering low-density lipoprotein cholesterol (LDL-C).
According to the ATP III report, the diagnosis of the meta-
bolic syndrome requires three or more of the following criteria:
waist circumference exceeding 102 and 88 cm for men and wo-
men, respectively, fasting triglycerides of 150 mg/dL or more
(_1.69 mmol/L), HDL-C less than 40 mg/dL (_1.0 mmol/L)
for men and less than 50 mg/dL (_1.3 mmol/L) for women,
blood pressure exceeding 130/85 mmHg, and fasting plasma
glucose levels of 110 mg/dL or more (_6.1 mmol/L) [14].
Interleukin-6 (IL-6), a 20.5 kDa protein containing 184
amino acid residues, is a multiple functional cytokine and crit-
ical to the regulation of the immune and haematopoietic sys-
tems. IL-6 induces the expression of acute phase proteins
and it is secreted by many different cell types, including T cells,
B cells, mast cells, monocytes, macrophages, ﬁbroblasts,
endothelial cells, keratinocytes and many tumor cell lines.
The aim of this work is to study the incidence of metabolic
syndrome in COPD patients and to evaluate the role of IL 6 as
a potent inﬂammatory marker in COPD patients with or with-
out metabolic syndrome.
Subjects and methods
The current study was carried out on 50 patients diagnosed as
having COPD (patient group) as well as 35 apparently healthy
non smoker volunteers with no history of chronic chest troubles
(control group). All the subjects were recruited from the Chest
Unit of Kasr El-Eini School of Medicine, Cairo University, inthe period between June 2011 and June 2012 after having given
their written informed consent prior to participation in the
study.
All patients and controls were analyzed for clinical and lab-
oratory ﬁndings, including full history taking, clinical exami-
nation, routine laboratory investigations including complete
blood picture with differential white cell count, erythrocyte
sedimentation rate, complete liver and kidney functions, serum
uric acid, serum LDH, lipid proﬁle including HDL-cholesterol,
triglycerides, as well as IL 6 level assay using the commercially
available ELISA kit (AviBion Human IL-6 ELISA provided
by Orgenium Laboratories, catalog number IL06001).
Body weight, height, and waist circumference were ob-
tained in all participants. Waist circumference was measured
by a single observer using an inelastic tape at the midpoint be-
tween the lowest rib and the iliac crest [15].
Blood pressure was taken from both arms and the higher
measurement was used for analysis.
Participants were asked to fast for 12 h before blood sam-
pling. Serum glucose concentration and triglycerides were
measured by an enzymatic colorimetric assay (Roche, Hitachi
917 analyzer). HDL-C was assessed by selective immunoinhi-
bition (Roche, Hitachi 917 analyzer).
Standard pulmonary function tests, in the form of spirom-
etry, was done for all COPD patients (see Table 1).
Statistical analysis
Data are reported as mean ± SD or proportions and 95%
conﬁdence intervals. Statistical analysis was performed by un-
paired t test and Fisher exact test. A value of P< 0.05 was
considered statistically signiﬁcant. A 1-way analysis of vari-
ance was performed to compare clinical characteristics be-
tween COPD patient group and control participant group.
Results
Baseline characteristics of all the subjects participated in the
study were summarized in Table 2. COPD patients and control
participants were matched for age, gender, and body mass in-
dex (Table 2).
There were no statistically signiﬁcant differences between the
patient and control group regarding age (P value = 0.3573), sex
(P value = 0.8861), body mass index (P value = 0.2503), dia-
stolic blood pressure (P value = 0.7465) and triglycerides (P va-
lue = 0.1779). There were statistically signiﬁcant differences
between the 2 groups regarding waist circumference (P va-
lue = 0.0158), systolic blood pressure (P value = 0.0157), high
density lipoprotein cholesterol (P value = 0.0264), fasting
blood glucose (P value<0.0001) and the incidence of metabolic
syndrome (P value = 0.0438). There was highly statistically
Table 2 Baseline characteristics of patients and controls.
Patients (COPD) (N= 50) Controls (N= 35) P value
Age (years) 57.7 ± 8.4 55.9 ± 9.4 0 .3573 [NS]
Sex (%)
Male 44 (88%) 32 (91.4%) 0.8861 [NS]
Female 6 (12%) 3 (8.6%)
BMI (kg/m2) 27 ± 4 28 ± 3.8 0.2503 [NS]
Waist circumference (cm) 114.3 ± 27.2 108.9 ± 22.4 0.0158 [S]
Systolic BP (mmHg) 128.4 ± 12.05 121.7 ± 12.8 0.0157 [S]
Diastolic BP (mmHg) 81.4 ± 10.3 82.1 ± 9.01 0.7465 [NS]
Triglycerides (mg/dl) 135.6 ± 17.83 140.4 ± 14.55 0.1779 [NS]
HDL cholesterol (mg/dl) 56.4 ± 9.79 51.97 ± 7.40 0.0264 [S]
Fasting glucose (mg/dl) 108.56 ± 17.61 86.91 ± 18.34 P< 0.0001 [HS]
Serum IL 6 assay (pg/ml) 0.38 ± 0.13 0.12 ± 0.1 P< 0.0001 [HS]
Metabolic syndrome (%) 20 (40%) 6 (17.1%) 0.0438 [S]
Not signiﬁcant [NS] (P value >0.05).
Signiﬁcant [S] (P value <0.05).
Highly signiﬁcant [HS] (P value <0.01).
Table 3 Summarizes the correlations between IL 6 and metabolic syndrome, FEV1 and abdominal waist.
Serum IL 6 level
Patients group (N= 50) Controls group (N= 35)
Metabolic syndrome r= 0.245 P= 0.021 [S] r= 0.175 P= 0.645 [NS]
FEV1 r= 0.36 P= 0.342 [NS]
Abdominal waist r= 0.24 P= 0.158 [NS]
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IL 6 level (P value <0.0001).
According to our results, we found that therewas statistically
signiﬁcant correlation between serum IL 6 level and the
incidence of metabolic syndrome in the patient group (P
value = 0.021) but not in the control group (P value = 0.645)
(summarized in Table 3).
We did not ﬁnd any statistically signiﬁcant correlation be-
tween serum IL 6 level and the results of FEV1 (r= 0.36) or
abdominal waist (r= 0.24) in the patient group (summarized
in Table 3).
Discussion
COPD is a growing cause of morbidity and mortality world-
wide, and will be the third leading cause of death by 2020
[16]. Systemic inﬂammation and physical inactivity have been
identiﬁed as relevant extrapulmonary marker of the severity
of COPD, as both conditions are related to exacerbations, hos-
pitalizations, and mortality in this patient population [17–20].
The origin of systemic inﬂammation in patients with COPD is
unclear [21]. In the general population, physical inactivity and
the metabolic syndrome are important determinants of sys-
temic inﬂammation [22,23].
The main ﬁnding of our study was that the presence of the
metabolic syndrome was more frequent in patients with COPD
than in the control group, with statistically signiﬁcant differ-
ences between the 2 groups (P value = 0.0438). Also serum
IL 6 level was higher in patients than controls with statistically
signiﬁcant differences between the 2 groups (P value <0.0001).The study done by Karine et al. [24] suggested that the pres-
ence of the metabolic syndrome may be frequent in patients
with COPD who participated in a cardiopulmonary rehabilita-
tion program.
In men with COPD, the prevalence of the metabolic syn-
drome was higher than the reported prevalence of the meta-
bolic syndrome in the general population. The US
population studied by Ford et al. was multiethnic in origin
[25]. Their sample of adults included 41% Caucasians, 28%
Mexican Americans, 27% African Americans, and 4% others
whereas COPD patients and control participants in our study
were all Egyptians. The metabolic syndrome varies substan-
tially among ethnic groups and these differences persisted even
after adjusting for contributing factors of the metabolic syn-
drome such as age, BMI, smoking and drinking habits, socio-
economic status, physical inactivity, and menopausal status
among women [26].
HDL-C levels were elevated in COPD patients, if compared
with the control group, with statistically signiﬁcant differences
between the 2 groups (P value = 0.0232). Karine et al. [24] re-
ported similar results of increased HDL-C in the patient group
if compared with the control group. Conversely, LDL-C levels
were lower in COPD patients compared to those in the control
participant group.
Tisi et al. [27] reported a similar ﬁnding and hypothesized
that the increased work of breathing might constitute a chronic
exercise stimulus for the respiratory muscles, resulting in an in-
crease in HDL-C levels. Although possible, it is doubtful that
respiratory muscles may have such a systemic impact. It has
also been suggested that the effects of some drugs, such as
88 H. Hosny et al.B2-agonists, might be responsible for an increased level of
HDL-C [27,28].
Also according to the study of Karine et al. [24] although
elevated HDL-C levels in COPD might exert protective effects
against cardiovascular diseases, it should be noted that the
proportion of patients with COPD encountering the dyslipi-
demic criteria (low HDL-C) of the metabolic syndrome was
still greater than to that of control.
It is important to emphasize that COPD often results in a
sedentary lifestyle and physical deconditioning, which could
explain the higher prevalence of the metabolic syndrome in
COPD patients compared to the control participant. COPD
is an important risk factor for cardiovascular disease, increas-
ing the risk by two- to three-folds [29,30,8]. However, the
mechanisms responsible for this association remain largely un-
known. It is recognized that patients with the metabolic syn-
drome are at increased risk for cardiovascular events. Thus,
in COPD patients, the presence of the metabolic syndrome
might explain in part the increment in cardiovascular diseases.
Also serum IL 6 level was higher in patients than controls
with statistically signiﬁcant differences between the 2 groups
(P value <0.0001).
According to the study done by Henrik et al. [31] who sta-
ted that the main ﬁnding of their study was that a considerable
number of patients with COPD of different severities have a
coexisting metabolic syndrome and that the coexisting meta-
bolic syndrome is associated with an increase in the levels of
some systemic inﬂammatory markers and physical inactivity
in these patients, irrespective of lung function impairment.
Markers of systemic inﬂammation have consistently been
found to be elevated in stable patients with COPD. Airway
obstruction failed to show substantial associations with sys-
temic inﬂammation in previous studies [32–34].
In conclusion, our ﬁndings suggest that the features of the
metabolic syndrome may be frequent in patients with COPD
than in the general population, so it is recommended to screen
all the COPD patients for associated metabolic syndrome as
well as elevated levels of inﬂammatory mediators.
References
[1] T.J. Thom, International comparisons in COPD mortality, Am.
Rev. Respir. Dis. 140 (1989) 27–34.
[2] C.J. Murray, A.D. Lopez, Mortality by cause for eight regions
of the world: global burden of disease study, Lancet 349 (1997)
1269–1276.
[3] C.J.L. Murray, A.D. Lopez, Alternative projections of mortality
and disability by cause 1990–2020: global burden of disease
study, Lancet 349 (1997) 1498–1504.
[4] C.M. Fletcher, R. Peto, The natural history of chronic airﬂow
obstruction, BMJ 1 (1978) 1645–1648.
[5] P.W. Jones, F.H. Quirk, C.M. Baveystock, The St. George’s
respiratoryquestionnaire,Respir.Med. 85 (Suppl. B) (1991) 25–31.
[6] N.R. Anthonisen, J.E. Connett, J.P. Kiley, et al, For the Lung
Health Study Research Group. Effects of smoking intervention
and the use of an anticholinergic bronchodilator on the rate of
decline in FEV1, JAMA 272 (1994) 1497–1505.
[7] D.A. Redelmeier, S.H. Tan, G.L. Booth, The treatment of
unrelated disorders in patients with chronic medical diseases, N.
Engl. J. Med. 338 (1998) 1516–1520.
[8] G. Engstro¨m, P. Lind, B. Hedblad, et al, Lung function and
cardiovascular risk: relationship with inﬂammation-sensitive
plasma proteins, Circulation 106 (2002) 2555–2560.[9] D.D. Sin, S.F. Man, Why are patients with chronic obstructive
pulmonary disease at increased risk of cardiovascular diseases?
The potential role of systemic inﬂammation in chronic
obstructive pulmonary disease, Circulation 107 (2003) 1514–
1519.
[10] G.L. Vega, Obesity, the metabolic syndrome, and
cardiovascular disease, Am. Heart J. 142 (2001) 1108–1116.
[11] National Institutes of Health, Third Report of the National
Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III), Executive Summary, NIH
Publication No. 01-3670, National Institutes of Health,
National Heart Lung and Blood Institute, Bethesda, MD, 2001.
[12] A. Lopez-Candales, Metabolic syndrome X: a comprehensive
review of the pathophysiology and recommended therapy, J.
Med. 32 (2001) 283–300.
[13] P. Bjorntorp, Heart and soul: stress and the metabolic
syndrome, Scand. Cardiovasc. J. 35 (2001) 172–177.
[14] Executive Summary of the Third Report of the National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III), JAMA 285
(2001) 2486–2497.
[15] P. Poirier, J.P. Despre´s, Waist circumference, visceral obesity,
and cardiovascular risk, J. Cardiopulm. Rehabil. 23 (2003) 161–
169.
[16] A.S. Buist, M.A. McBurnie, W.M. Vollmer, et al, International
variation in the prevalence of COPD (the BOLD Study): a
population-based prevalence study, Lancet 370 (2007) 741–750.
[17] K.H. Groenewegen, D.S. Postma, W.C. Hop, et al, Increased
systemic inﬂammation is a risk factor for COPD exacerbations,
Chest 133 (2008) 350–357.
[18] M. Dahl, J. Vestbo, P. Lange, et al, C-reactive protein as a
predictor of prognosis in chronic obstructive pulmonary disease,
Am. J. Respir. Crit. Care Med. 175 (2007) 250–255.
[19] S.F. Man, J.E. Connett, N.R. Anthonisen, et al, C-reactive
protein and mortality in mild to moderate chronic obstructive
pulmonary disease, Thorax 61 (2006) 849–853.
[20] J. Garcia-Aymerich, E. Farrero, M.A. Felez, et al, Risk factors
of readmission to hospital for a COPD exacerbation: a
prospective study, Thorax 58 (2003) 100–105.
[21] A. Agusti, Systemic effects of chronic obstructive pulmonary
disease: what we know and what we don’t know (but should),
Proc. Am. Thorac. Soc. 4 (2007) 522–525.
[22] S. Mora, I.M. Lee, J.E. Buring, et al, Association of physical
activity and body mass index with novel and traditional
cardiovascular biomarkers in women, JAMA 295 (2006) 1412–
1419.
[23] B. Thorand, J. Baumert, A. Doring, et al, Sex differences in the
relation of body composition to markers of inﬂammation,
Atherosclerosis 184 (2006) 216–224.
[24] M. Karine, M. Franc¸ois, D. Ve´ronique, et al, The metabolic
syndrome in patients with chronic obstructive pulmonary
disease, J. Cardiopulm. Rehabil. 25 (2005) 226–232.
[25] E.S. Ford, W.H. Giles, W.H. Dietz, Prevalence of the metabolic
syndrome among US adults: ﬁndings from the Third National
Health and Nutrition Examination Survey, JAMA 287 (2002)
356–359.
[26] Y.W. Park, S. Zhu, L. Palaniappan, et al, The metabolic
syndrome: prevalence and associated risk factor ﬁndings in the
US population from the Third National Health and Nutrition
Examination Survey, 1988–1994, Arch. Intern. Med. 163 (2003)
427–436.
[27] G.M. Tisi, A. Conrique, E. Barrett-Connor, S.M. Grundy,
Increased high density lipoprotein cholesterol in obstructive
pulmonary disease (predominant emphysematous type),
Metabolism 30 (1981) 340–346.
Metabolic syndrome and systemic inﬂammation in COPD patients 89[28] C.H. Bolton, E. Mulloy, J. Harvey, et al, Plasma and
lipoprotein lipids and apolipoproteins AI, AII, and B in
patients with chronic airﬂow limitation, J. R. Soc. Med. 82
(1989) 91–92.
[29] G.D. Friedman, A.L. Klatsky, A.B. Siegelaub, Lung function
and risk of myocardial infarction and sudden cardiac death, N.
Engl. J. Med. 294 (1976) 1071–1075.
[30] D.J. Hole, G.C. Watt, G. Davey-Smith, et al, Impaired lung
function and mortality risk in men and women: ﬁndings from
the Renfrew and Paisley prospective population study, BMJ 313
(1996) 711–715.
[31] W. Henrik, W. Benjamin, K. Anne, et al, The metabolic
syndrome in patients with chronic bronchitis and COPDfrequency and associated consequences for systemic
inﬂammation and physical inactivity, Chest 136 (4) (2009).
[32] R. Broekhuizen, E.F. Wouters, E.C. Creutzberg, et al, Raised
CRP levels mark metabolic and functional impairment in
advanced COPD, Thorax 61 (2006) 17–22.
[33] V.M. Pinto-Plata, H. Mullerova, J.F. Toso, et al, C-reactive
protein in patients with COPD, control smokers and
nonsmokers, Thorax 61 (2006) 23–28.
[34] J.P. de Torres, E. Cordoba-Lanus, C. Lopez-Aguilar, et al, C-
reactive protein levels and clinically important predictive
outcomes in stable COPD patients, Eur. Respir. J. 27 (2006)
902–907.
